Evaxion Biotech
EVAX | NASDAQ
$2.77
+$0.03 (+0.96%)
At close: Nov 16, 2026, 4:00 PM ET
$2.77
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
Evaxion Biotech Company Profile
Company profile explainedCompany Profile
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Key Executives
| Name | Position |
|---|---|
| Helen Katrina Tayton-Martin | Chief Executive Officer |
| Thomas Frederik Schmidt | Chief Financial Officer |
| Andreas Holm Mattsson | Founder & Chief AI Officer |
| Benjamin Ole Wolthers | Vice President of Clinical Development |
| Birgitte Rono | Chief Scientific Officer & COO |
Evaxion Biotech
| Country | Denmark |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Helen Katrina Tayton-Martin |
Contact Details
Dr. Neergaards Vej Horsholm,
North Dakota 2970 Denmark
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828253 |
| CUSIP Number | 29970R303 |
| ISIN Number | US29970R3030 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove EVAX